Sugarloaf Wealth Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Sugarloaf Wealth Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150	Closed	-$5K	–	894
2022 Q2	$5K	Hold	150	–	–	﹤0.01%	618
2022 Q1	$5K	Hold	150	–	–	﹤0.01%	578
2021 Q4	$4K	Hold	150	–	–	﹤0.01%	628
2021 Q3	$4K	Sell	150 -250	-63%	-$7.35K	﹤0.01%	641
2021 Q2	$14K	Hold	400	–	–	﹤0.01%	465
2021 Q1	$16	Hold	400	–	–	﹤0.01%	454
2020 Q4	$17K	Buy	400 +50	+14%	+$2.46K	0.01%	415
2020 Q3	$19K	Hold	350	–	–	0.01%	370
2020 Q2	$22K	Hold	350	–	–	0.01%	341
2020 Q1	$18K	Hold	350	–	–	0.01%	353
2019 Q4	$28K	Buy	+350	New	+$20.7K	0.01%	325

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sugarloaf Wealth Management's GBT Position: Q3 2022 in Review

Sugarloaf Wealth Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 150 shares — an estimated $5K sold.

Sugarloaf Wealth Management first reported a position in GBT in Q4 2019 and held it in 11 quarters. The position peaked at $28K in Q4 2019. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Sugarloaf Wealth Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Sugarloaf Wealth Management sold 150 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $5K.
Sugarloaf Wealth Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 11 quarters.
Sugarloaf Wealth Management's Global Blood Therapeutics, Inc. position peaked at $28K in Q4 2019.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Sugarloaf Wealth Management's 13F filing for Q3 2022, filed 11 Oct 2022.